When a 30-person Austrian startup gets showcased by Jensen Huang, CEO of the trillion-dollar tech giant NVIDIA, schedules tend to fill up fast. That’s precisely the case for Innophore, a biotech company tapping NVIDIA’s computational clout with its Catalophore platform to accelerate AI-driven drug safety screening and binding-site analysis. This year, the company was highlighted…